Creative Planning’s Aclaris Therapeutics ACRS Stock Holding History

Creative Planning’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$570K	Buy	152,088 +100,917	+197%	+$341K	﹤0.01%	2927
2025 Q4	$154K	Buy	+51,171	New	+$129K	﹤0.01%	3630
2021 Q2	–	Sell	-17,740	Closed	-$447K	–	2058
2021 Q1	$447K	Sell	17,740 -2,760	-13%	-$54K	﹤0.01%	1513
2020 Q4	$133K	Sell	20,500 -9,500	-32%	-$40.1K	﹤0.01%	1982
2020 Q3	$77K	Sell	30,000 -76	-0.3%	-$170	﹤0.01%	1861
2020 Q2	$49K	Hold	30,076	–	–	﹤0.01%	1767
2020 Q1	$31K	Hold	30,076	–	–	﹤0.01%	1685
2019 Q4	$57K	Hold	30,076	–	–	﹤0.01%	1810
2019 Q3	$32K	Buy	+30,076	New	+$42.7K	﹤0.01%	1826

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Creative Planning's ACRS Position: Q1 2026 in Review

Creative Planning increased its Aclaris Therapeutics (ACRS) stake by 197% in Q1 2026, buying an estimated $341K and bringing the position to 152,088 shares worth $570K. The position accounts for ﹤0.01% of the portfolio, ranked #2927.

Creative Planning first reported a position in ACRS in Q3 2019 and has held it in 9 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Creative Planning held 152,088 shares of Aclaris Therapeutics worth $570K as of Q1 2026.
Creative Planning bought 100,917 Aclaris Therapeutics shares in Q1 2026, an estimated $341K.
Aclaris Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #2927 holding.
Creative Planning first reported a position in Aclaris Therapeutics in Q3 2019 and has held it in 9 quarters since.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.